Soluble Nogo-A, an inhibitor of axonal regeneration, as a biomarker for multiple sclerosis

Neurology

Volumn 68, Issue 4, 2007, Pages 283-287

  Jurewicz, Anna ^a   Matysiak, Mariola ^a   Raine, Cedric S ^b   Selmaj, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROTEIN NOGO A;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; ENCEPHALOMYELITIS; FEMALE; HUMAN; HUMAN TISSUE; MALE; MENINGOENCEPHALITIS; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NERVE FIBER REGENERATION; NERVOUS TISSUE; NEUROLOGIC DISEASE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; AXONS; BIOLOGICAL MARKERS; HUMANS; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN PROTEINS; NERVE REGENERATION; NEURAL INHIBITION; PREDICTIVE VALUE OF TESTS; SOLUBILITY;

EID: 33846459970     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000252357.30287.1d     Document Type: Article

References (31)

1. Gianola S, Savio T, Schwab ME, Rossi F. Cell-autonomous mechanisms and myelin-associated factors contribute to the development of Purkinje axon intracortical plexus in the rat cerebellum. J Neurosci 2003;23:4613-4624.
2. Meier S, Brauer AU, Heimrich B, Schwab ME, Nitsch R, Savaskan NE. Molecular analysis of Nogo expression in the hippocampus during development and following lesion and seizure. FASEB J 2003;17:1153-1155.
3. McKerracher L, David S, Jackson JL, Kottis V, Dunn R, Braun PE. Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth. Neuron 1994;13:805-811.
4. Mukhopadhyay G, Doherty P, Walsh FS, Crocker PR, Fibin MT. A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration. Neuron 1994;13:757-767.
5. Kottis V, Thibault P, Mikol D, et al. Oligodendrocyte-myelin glycoprotein (OMgp) is an inhibitor of neurite outgrowth. J Neurochem 2002;82:1566-1569.
6. Tanaka M, Maeda N, Noda M, Marunouchi T. Chondroitin sulfate proteoglycan PTPzeta /RPTPbeta regulates the morphogenesis of Purkinje cell dendrites in the developing cerebellum. J Neurosci 2003;23:2804-2814.
7. Garwood J, Rigato F, Heck N, Faissner A. Tenascin glycoproteins and the complementary ligand DSD-1-PG/ phosphacan-structuring the neural extracellular matrix during development and repair. Restor Neurol Neurosci 2001;19:51-64.
8. Yamauchi S, Tokita Y, Aono S, et al. Phosphorylation of neuroglycan C, a brain-specific transmembrane chondroitin sulfate proteoglycan, and its localization in the lipid rafts. J Biol Chem 2002;277:20583-20590.
9. Chen MS, Huber AB, van der Haar ME, et al. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen formonoclonal antibody IN-1. Nature 2000;403:435-439.
10. Prinjha R, Moore SE, Vinson M, et al. Inhibitor of neurite outgrowth in humans. Nature 2000;403:383-384.
11. GrandPre T, Nakamura F, Vartanian T, Strittmatter SM. Identification of the Nogo inhibitor of axon regeneration as a reticulon protein. Nature 2000;403:439-444.
12. Buffo A, Zagrebelsky M, Huber AB, et al. Application of neutralizing antibodies against NI-35/250 Myelin-Associated Neurite Growth Inhibitory Proteins to the adult rat cerebellum induces sprouting of uninjured Purkinje cell axons. J Neurosci 2000;20:2275-2286.
13. Merkler D, Metz GAS, Raineteau O, Dietz V, Schwab ME, Fouad K. Locomotor recovery in spinal cord-injured rats treated with an antibody neutralizing the myelin-associated neurite growth inhibitor Nogo-A. J Neurosci 2001;21:3665-3673.
14. Oertle T, Huber C, van der Putten H, Schwab ME. Genomic structure and functional characterization of the promoters of human and mouse nogo/rtn4. J Mol Biol 2003;325:299-323.
15. Fournier AE, GrandPre T, Strittmatter SM. Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature 2001;409:341-346.
16. Huber AB, Weinmann O, Brosamle C, Oertle T, Schwab ME. Patterns of nogo mRNA and protein expression in the developing and adult rat after CNS lesions. J Neurosci 2002;22:3553-3567.
17. Geisler JG, Stubbs LJ, Wasserman WW, Mucenski ML. Molecular cloning of novel mouse gene with predominant muscle and neural expression. Mamm Genome 1998;9:979-982.
18. Dupuis L, Gonzalez de Aguilar JL, di Scala F, et al. Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis. Neurobiol Dis 2002;10:358-365.
19. Bjartmar C, Kinkel RP, Kidd G, Rudick RA, Trapp BD. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 2001;57:1248-1252. (a)
20. Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 2001;14:271-278. (b)
21. Bjartmar C, Trapp BD. Axonal degeneration and progressive neurologic disability in multiple sclerosis. Neurotox Res 2003;5:157-164.
22. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-127.
23. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059-2069.
24. Walmsley AR, McCombie G, Neumann U, et al. Zinc metalloproteinase- mediated cleavage of human Nogo receptor. J Cell Sci 2004;117:4591-4602.
25. Frohman EM, Racke MK, Raine CS. Multiple sclerosis: the plaque and its pathogenesis. N Engl J Med 2006;354:942-955.
26. Tang S, Qiu J, Nikulina E, Filbin MT. Soluble myelin-associated glycoprotein released from damaged white matter inhibits axonal regeneration. Molec Cell Neurosci 2001;18:259-269.
27. GrandPre T, Li S, Strittmatter SM. Nogo-66 receptor antagonist peptide promotes axonal regeneration. Nature 2002;417:547-551.
28. Karnezis T, Mandemakers W, McQualter JL, et al. The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination. Nat Neurosci 2004;7:736-744.
29. Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003;349:139-145.
30. Reindl M, Khantane S, Ehling R, et al. Serum and cerebrospinal fluid antibodies to Nogo-A in patients with multiple sclerosis and acute neurological disorders. J Neuroimmunol 2003;145:139-147.
31. Whitaker JN. Myelin basic protein in cerebrospinal fluid and other body fluids. Mult Scler 1998;4:16-21.